| AJNMMI Copyright © 2011-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA |
Am J Nucl Med Mol Imaging 2012;2(3):353-361
Original Article
Bioluminescence imaging of therapy response does not correlate with FDG-PET
response in a mouse model of Burkitt lymphoma
Marijke De Saint-Hubert, Ellen Devos, Abdelilah Ibrahimi, Zeger Debyser, Luc Mortelmans, Felix M Mottaghy
Department of Nuclear Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Nuclear
Medicine, Katholieke Universiteit Leuven, Leuven, Belgium; Laboratory for Molecular Virology and Gene Therapy, Katholieke
Universiteit Leuven, Leuven, Belgium; Klinik für Nuklearmedizin, UKA, RWTH Aachen, Germany
Received May 8, 2012; accepted June 5, 2012; Epub July 10, 2012; Published Juy 30, 2012
Abstract: Since the development and evaluation of novel anti-cancer therapies require molecular insight in the disease state, both
FDG-PET and BLI imaging were evaluated in a Burkitt B-cell lymphoma xenograft model treated with cyclophosphamide or
temsirolimus. Daudi xenograft mice were treated with either cyclophosphamide or temsirolimus and imaged with BLI and FDG-PET
on d0 (before treatment), d2, d4, d7, d9 and d14 following the start of therapy. Besides tumor volume changes, therapy response
was assessed with immunohistochemical analysis (apoptosis). BLI revealed a flare following both therapeutics that was
significantly higher when compared to control tumors. FDG-PET decreased immediatelly, long before the tumor reduced in size. Late
after therapy, BLI signal intensities decreased significantly compared to baseline subsequent to tumor size reduction while
apoptosis was immediately induced following both treatment regimen. Unlike FDG, BLI was not able to reflect reduced levels of
viable cells and was not able to predict tumor size response and apoptosis response. (ajnmmi1205001).
Keywords: Bioluminescence imaging, therapy response, FDG-PET
Address all correspondence to:
Dr. Mottaghy FM
Klinik für Nuklearmedizin
Universitätsklinikum der RWTH Aachen
Pauwelsstraße 30, 52074
Aachen, Germany.
Tel: +49-241-8088740
E-mail: fmottaghy@ukaachen.de
Original Article
Bioluminescence imaging of therapy response does not correlate with FDG-PET
response in a mouse model of Burkitt lymphoma
Marijke De Saint-Hubert, Ellen Devos, Abdelilah Ibrahimi, Zeger Debyser, Luc Mortelmans, Felix M Mottaghy
Department of Nuclear Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Nuclear
Medicine, Katholieke Universiteit Leuven, Leuven, Belgium; Laboratory for Molecular Virology and Gene Therapy, Katholieke
Universiteit Leuven, Leuven, Belgium; Klinik für Nuklearmedizin, UKA, RWTH Aachen, Germany
Received May 8, 2012; accepted June 5, 2012; Epub July 10, 2012; Published Juy 30, 2012
Abstract: Since the development and evaluation of novel anti-cancer therapies require molecular insight in the disease state, both
FDG-PET and BLI imaging were evaluated in a Burkitt B-cell lymphoma xenograft model treated with cyclophosphamide or
temsirolimus. Daudi xenograft mice were treated with either cyclophosphamide or temsirolimus and imaged with BLI and FDG-PET
on d0 (before treatment), d2, d4, d7, d9 and d14 following the start of therapy. Besides tumor volume changes, therapy response
was assessed with immunohistochemical analysis (apoptosis). BLI revealed a flare following both therapeutics that was
significantly higher when compared to control tumors. FDG-PET decreased immediatelly, long before the tumor reduced in size. Late
after therapy, BLI signal intensities decreased significantly compared to baseline subsequent to tumor size reduction while
apoptosis was immediately induced following both treatment regimen. Unlike FDG, BLI was not able to reflect reduced levels of
viable cells and was not able to predict tumor size response and apoptosis response. (ajnmmi1205001).
Keywords: Bioluminescence imaging, therapy response, FDG-PET
Address all correspondence to:
Dr. Mottaghy FM
Klinik für Nuklearmedizin
Universitätsklinikum der RWTH Aachen
Pauwelsstraße 30, 52074
Aachen, Germany.
Tel: +49-241-8088740
E-mail: fmottaghy@ukaachen.de
 |  |  |  |  |  |  |